Quercetin Alleviates Cardiac Fibrosis via Regulating the SIRT3 Signaling Pathway.

IF 3.1 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Cardiovascular Drugs and Therapy Pub Date : 2024-12-16 DOI:10.1007/s10557-024-07658-x

Da-Wei Lin, Yi-Wen Jiang, Chen Wu, Hao Zhang, Ying-Ze Li, Yao-Sheng Wang

{"title":"Quercetin Alleviates Cardiac Fibrosis via Regulating the SIRT3 Signaling Pathway.","authors":"Da-Wei Lin, Yi-Wen Jiang, Chen Wu, Hao Zhang, Ying-Ze Li, Yao-Sheng Wang","doi":"10.1007/s10557-024-07658-x","DOIUrl":null,"url":null,"abstract":"Purpose: Cardiovascular diseases, exacerbated by cardiac fibrosis, are the leading causes of mortality. We aimed to determine the role of quercetin (QU) in cardiac fibrosis and the underlying mechanism.Methods: In this study, 8-week-old mice were subjected to either transverse aortic constriction (TAC) or sham surgery, then they were administered QU or saline. Thereafter, cardiac function and cardiac hypertrophy were accessed. In vitro, cardiac fibroblasts (CFs) were treated with angiotensin II (Ang II) with or without QU. Western blot, qPCR, EdU incorporation assay, and immunofluorescence staining analysis were used to investigate the molecular and cellular features.Results: For the TAC mouse model, cardiac fibrosis was alleviated by QU. The study revealed that the trans-differentiation and proliferation of CFs promoted by Ang II would be reversed by QU in vitro. Mechanistically, QU exerted the anti-fibrotic effect by regulating the SIRT3/TGF-β/Smad3 signaling pathway.Conclusion: Quercetin protects against cardiac fibrosis by mediating the SIRT3 signaling pathway.","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Drugs and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10557-024-07658-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Cardiovascular diseases, exacerbated by cardiac fibrosis, are the leading causes of mortality. We aimed to determine the role of quercetin (QU) in cardiac fibrosis and the underlying mechanism.

Methods: In this study, 8-week-old mice were subjected to either transverse aortic constriction (TAC) or sham surgery, then they were administered QU or saline. Thereafter, cardiac function and cardiac hypertrophy were accessed. In vitro, cardiac fibroblasts (CFs) were treated with angiotensin II (Ang II) with or without QU. Western blot, qPCR, EdU incorporation assay, and immunofluorescence staining analysis were used to investigate the molecular and cellular features.

Results: For the TAC mouse model, cardiac fibrosis was alleviated by QU. The study revealed that the trans-differentiation and proliferation of CFs promoted by Ang II would be reversed by QU in vitro. Mechanistically, QU exerted the anti-fibrotic effect by regulating the SIRT3/TGF-β/Smad3 signaling pathway.

Conclusion: Quercetin protects against cardiac fibrosis by mediating the SIRT3 signaling pathway.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

槲皮素通过调节 SIRT3 信号通路缓解心脏纤维化

目的：因心脏纤维化而恶化的心血管疾病是导致死亡的主要原因。我们旨在确定槲皮素（QU）在心脏纤维化中的作用及其内在机制：方法：本研究对 8 周大的小鼠进行横纹主动脉缩窄术（TAC）或假手术，然后给小鼠注射槲皮素或生理盐水。此后，对小鼠的心脏功能和心脏肥大进行检测。在体外，用血管紧张素 II（Ang II）处理心脏成纤维细胞（CFs），加入或不加入 QU。采用 Western 印迹、qPCR、EdU 结合测定和免疫荧光染色分析来研究分子和细胞特征：结果：对于 TAC 小鼠模型，QU 可减轻心脏纤维化。研究发现，QU能在体外逆转Ang II促进的CFs转分化和增殖。从机制上讲，QU通过调节SIRT3/TGF-β/Smad3信号通路发挥抗纤维化作用：结论：槲皮素通过调节SIRT3信号通路保护心脏纤维化。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cardiovascular Drugs and Therapy 医学-心血管系统

CiteScore

8.30

自引率

0.00%

发文量

110

审稿时长

4.5 months

期刊介绍： Designed to objectively cover the process of bench to bedside development of cardiovascular drug, device and cell therapy, and to bring you the information you need most in a timely and useful format, Cardiovascular Drugs and Therapy takes a fresh and energetic look at advances in this dynamic field. Homing in on the most exciting work being done on new therapeutic agents, Cardiovascular Drugs and Therapy focusses on developments in atherosclerosis, hyperlipidemia, diabetes, ischemic syndromes and arrhythmias. The Journal is an authoritative source of current and relevant information that is indispensable for basic and clinical investigators aiming for novel, breakthrough research as well as for cardiologists seeking to best serve their patients. Providing you with a single, concise reference tool acknowledged to be among the finest in the world, Cardiovascular Drugs and Therapy is listed in Web of Science and PubMed/Medline among other abstracting and indexing services. The regular articles and frequent special topical issues equip you with an up-to-date source defined by the need for accurate information on an ever-evolving field. Cardiovascular Drugs and Therapy is a careful and accurate guide through the maze of new products and therapies which furnishes you with the details on cardiovascular pharmacology that you will refer to time and time again.